Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects
Capturing the earliest stages of Dementia especially Alzheimer's Disease (AD) is a great challenge. Until now the NINCDS-ADRDA and the DSM criteria for AD were largely used as diagnostic standards in research. However, the research on AD progresses and some biomarkers have been recently suggested to improve the diagnostic criteria of AD, such as cerebrospinal fluid markers, neuroimaging with...
Brief Summary
Official Title: “Estimation of Microstructure Alteration by MRI in Dementia Among Elderly Subjects Retired From Agricultural Profession and Living in Rural Area in Gironde - Participants From the AMI Cohort.”
Capturing the earliest stages of Dementia especially Alzheimer's Disease (AD) is a great challenge. Until now the NINCDS-ADRDA and the DSM criteria for AD were largely used as diagnostic standards in research. However, the research on AD progresses and some biomarkers have been recently suggested to improve the diagnostic criteria of AD, such as cerebrospinal fluid markers, neuroimaging with Positon Emission Tomography (PET) or Magnetic Resonance Imaging (MRI).
- Study Type: Observational
- Study Design: Observational Model: Ecologic or Community, Time Perspective: Prospective
- Study Primary Completion Date: March 2011
Intervention(s) in this Clinical Trial
- Other: Neuroimaging
- Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
Arms, Groups and Cohorts in this Clinical Trial
- : elderly subjects retired from agriculture
Outcome Measures for this Clinical Trial
Primary Measures
- FA (Fractional Anisotropy), MTR (magnetization transfer ratio) and T2 (Transverse relaxation time) measures in patients with dementia compared to controls, in left and right hippocampus, and posterior cingulum
- Time Frame: day 0
Safety Issue?: No
- Time Frame: day 0
Secondary Measures
- FA, MTR and T2 measures in subjects with mild cognitive impairment no dementia
- Time Frame: day 0
Safety Issue?: No
- Time Frame: day 0
- Performances in the 7 neuropsychological tests available in the AMI cohort
- Time Frame: day 0
Safety Issue?: No
- Time Frame: day 0
- FA measures for the connexion Hippocampus-cingulum posterior
- Time Frame: day 0
Safety Issue?: No
- Time Frame: day 0
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- participate in the AMI cohort
- be aged 65 and older
- be retired from agricultural profession
- live in rural area in Gironde
Exclusion Criteria:
- contraindication of MRI
- left-handed
- severe dementia
- Parkinson's disease
- poor health incompatible with the transport to neuroimaging service
- to be left handed
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 65 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: University Hospital, Bordeaux Other
Overall Clinical Trial Officials and Contacts
Michèle ALLARD Principal Investigator University Hospital, Bordeaux
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00951197
Study ID Number: CHUBX2008/13
ClinicalTrials.gov Identifier: NCT00951197
Health Authority: France: Afssaps - French Health Products Safety Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00951197
